Overview

A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC

Status:
Completed
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the effect of seladelpar treatment compared to placebo on efficacy, safety, and tolerability in patients with primary sclerosing cholangitis (PSC).
Phase:
Phase 2
Details
Lead Sponsor:
CymaBay Therapeutics, Inc.
Treatments:
Seladelpar